ArticleCell death & disease2026
Endothelial IRE1 signaling maintains blood-brain barrier integrity and limits neuroinflammation after traumatic brain injury.
Article in Cell death & disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Endoplasmic reticulum (ER) stress and activation of the unfolded protein response (UPR) contribute to the pathogenesis of traumatic brain injury (TBI), yet the cell type-specific roles of UPR pathways remain poorly understood. We previously identified endothelial cells (ECs) as a primary site of IRE1 pathway activation following brain injury. In this study, we investigated the role of endothelial IRE1 signaling in TBI using EC-specific IRE1 conditional knockout mice subjected to cortical ablation. Loss of IRE1 in ECs exacerbated blood-brain barrier (BBB) disruption, enhanced immune cell infiltration, amplified neuroinflammation, and expanded neuronal damage, ultimately leading to worsened neurological outcomes. RNA-sequencing revealed enrichment of interferon-related programs and identified Cxcl10 as an endothelial chemokine linked to the exacerbated leukocyte recruitment in endothelial IRE1 deficiency. Treatment with the chemical chaperone tauroursodeoxycholic acid (TUDCA) suppressed Cxcl10 expression both in vitro and in vivo, and significantly improved motor function following TBI. These findings reveal a critical role for endothelial IRE1 signaling in maintaining BBB integrity and restraining inflammation during the acute phase of TBI. Modulation of ER stress in brain ECs may represent a promising and accessible therapeutic strategy for reducing secondary injury after TBI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.